Data Presented to FDA Panel Show TAXUS(TM) Drug-Eluting Stents as Safe as Bare-Metal Stents and Far More Effective in Reducing Repeat Procedures

Boston Scientific Corporation (NYSE: BSX) yesterday presented data on its long-term randomized clinical trials to a special U.S. Food and Drug Administration (FDA) panel, showing that the TAXUS(TM) paclitaxel-eluting coronary stent is as safe as bare-metal stents (BMS), and far more effective in keeping arteries open and reducing the need for repeat procedures.

The data presented by Dr. Donald Baim, Chief Medical and Scientific Officer for Boston Scientific, were based on a detailed analysis of 2,797 patients from four randomized TAXUS clinical trials who received TAXUS or BMS for approved indications and were followed closely for four years. The data showed that the TAXUS stent reduced the need to retreat vessels due to restenosis by nearly 50 percent compared to BMS.

The very late stent thrombosis rate for the TAXUS stent group is not statistically different from the BMS control group, according to any of the available definitions. There is no evidence of any increase in clinical complications in the TAXUS stent group, and favorable risk-benefit outcomes were seen in important trial subgroups, including patients with diabetes, small

vessels and multiple stents per vessel.

"When used for approved indications, the TAXUS stent is twice as effective as BMS in keeping vessels open, helping patients stay healthy, and avoid restenosis and the need for repeat procedures," said Dr. Baim. "It is important to understand that restenosis is not benign. Overall, the total number of deaths in the TAXUS stent group was the same or slightly lower than the BMS group throughout the four years following the procedure."

"We have continued to be forthcoming and transparent with the clinical data related to our DES because we believe it is important to help doctors and patients make the best and most informed decisions," said Dr. Baim.

Dr. Baim said the risk of stent thrombosis is greatest in the first year following implantation, and drops off to very low levels thereafter for both BMS and drug-eluting stents (DES), a finding corroborated by other studies. Boston Scientific is continuing to study stent thrombosis and has agreed to provide lead financial support for an extension of the independent STENT registry, which will include the enrollment of an additional 10,000 DES patients.

Dr. Baim went on to present data indicating that patients have a far better chance of avoiding blood clots if they take anti-clotting drugs for six or more months after a stenting procedure. The data is consistent with current published recommendations from the American Heart Association and American College of Cardiology Guidelines for these procedures. The adoption of longer

Boston Scientific also presented data on its 7,000-patient ARRIVE I and II registries of real-world patients including those with complex lesions. While the TAXUS randomized clinical trials focused on patients who received a single stent to relieve a blockage in a single vessel, the patients enrolled in the ARRIVE registries tended to present much more complex situations involving very

The data presented by Dr. Baim showed that patients in the ARRIVE registries with simple blockages had comparable outcomes to those with similar lesions in the TAXUS clinical trials, confirming the ability of these registries to accurately track clinical outcomes. As expected, patients with complex coronary artery disease had slightly higher adverse events compared to the randomized trials and the simpler cases in the ARRIVE registries. However, the rates of death and heart attack were equivalent or better than those for potential alternative treatments such as bypass surgery. The data on complex cases were also consistent with real-world registries of DES using either the TAXUS or the CYPHER(TM) stents. These registries showed trends towards lower

"The patients treated in ARRIVE had such complex disease that many would have been poor candidates for BMS or conventional angioplasty," said Dr. Baim. "They were just too sick and the standard treatment for many of these patients

The FDA panel, which will conclude two days of hearings on Friday, first considered data involving approved uses of DES before moving to uses by interventional cardiologists for other kinds of cases, many of them involving complex heart disease or subsets like diabetic patients.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property,

SOURCE: Boston Scientific Corporation

CONTACT: Geraldine Varoqui,

Boston Scientific PR Manager International,

+49-2102-489-461,

[email protected] ; or

Tracy Paul,

BSC press office,

+44-20-7413-3101,

[email protected]

Web site: http://www.bostonscientific.com

--Distributed by AsiaNet ( www.asianetnews.net )--

• ข่าวBoston Scientific
• ข่าวo:heal
• ข่าวo:asn
• ข่าวo:eco
• ข่าวen